Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

被引：0
作者：
Shunji Takahashi
机构：
[1] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Medical Oncology
来源：
Journal of Bone and Mineral Metabolism | 2023年 / 41卷
关键词：
Breast cancer; Prostate cancer; Cancer-therapy induced bone loss; Bisphosphonates; Denosumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Breast cancer and prostate cancer are sex hormone-dependent cancers, and estrogen or androgen suppression therapy is the standard treatment. Cancer treatment-induced bone loss (CTIBL): bone loss and osteoporosis have become important side effects of these therapies. To summarize the current evidences, (1) Endocrine therapy for breast cancer and prostate cancer is associated with a significant decrease in bone mineral density. (2) Aromatase inhibitors (AI) for breast cancer are associated with a significant increase in fractures, and androgen deprivation therapy (ADT) for prostate cancer is likely to be associated with an increase in fractures. (3) Administration of bisphosphonates and denosumab increases bone mass in patients undergoing endocrine therapy for breast cancer. Administration of bisphosphonates, denosumab, and SERMs increased bone mass in patients undergoing ADT therapy for prostate cancer. (4) Bisphosphonates and denosumab reduce fracture risk in patients on AI for breast cancer, and toremifene and denosumab in patients on ADT for prostate cancer.
引用
收藏
页码：307 / 316
页数：9
相关论文
共 286 条
  • [21] Powles TJ(2015)Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy Osteoporos Int 26 1175-381
  • [22] Hickish T(2008)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 376-693
  • [23] Kanis JA(2022)Biological effects of cyclin-dependent kinase inhibitors ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment Int J Mol Sci 23 685-T38
  • [24] Stumpf U(2006)Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference? Ann Oncol 17 T19-1324
  • [25] Kostev K(2010)Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy Oncology 79 1317-186
  • [26] Kyvernitakis J(2012)Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results Breast Cancer Res Treat 133 181-3661
  • [27] Pagani O(2021)Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer Endocr Relat Cancer 28 3656-2367
  • [28] Regan MM(2016)A concise review of testosterone and bone health Clin Interv Aging 11 2361-2553
  • [29] Walley BA(2000)Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2546-2276
  • [30] Hadji P(2002)Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs J Clin Endocrinol Metab 87 2272-1683
12345678910